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Psoriasis is a chronic, relapsing skin disease characterized by enhanced angiogenesis. The pathogenetic process
resulting in hypervascularity remains to be further investigated. It has been reported that a potent angiogenic
factor, vascular endothelial growth factor (VEGF) is overexpressed in psoriatic epidermis and that the level of
insulin-like growth factor II (IGF-II) is signiﬁcantly elevated in the tissue ﬂuid and serum of the psoriatic lesion. We
considered the possibility that IGF-II might function as a paracrine inducer of VEGF. Here, we demonstrated that
exposure of HaCaT keratinocytes to IGF-II induced both mRNA and protein expression of VEGF through the MAP
kinase (extracellular signal-regulated kinase (ERK2) pathway. Particularly, we determined that phosphorylation of
ERK2 but not p38 and JNK1/2 was activated by IGF-II in a time-dependent manner. Additionally, we found that IGF-II
treatment induced the expression of MDM2 through the MAP kinase pathway. Moreover, the increase of MDM2
resulted in decreased levels of p53 followed by increased expression of HIF-1a and VEGF. Taken together, these
results suggest that IGF-II enhances the expression of VEGF in HaCaT cells by increasing HIF-1a levels.
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Psoriasis is a common, chronic skin disease characterized
by recurrent erythematous skin plaques that exhibit
epidermal hyperplasia (Weinstein et al, 1985; Baker and
Fry, 1992), a variable inflammatory cell infiltrate, and angio-
proliferation (Braverman and Keh-Yen, 1986). Capillaries
in the papillary dermis of lesions are elongated, dilated,
tortuous, and hyperpermeable (Mordovtsev and Albanova,
1989). These findings indicate a critical pathogenetic role for
microvascular expansion in lesional skins and have led to
the suggestion that psoriasis is an angiogenesis-dependent
disease (Folkman, 1972; Beranek, 1990; Creamer et al,
1997).
Previous studies demonstrated that a potent angiogenic
factor vascular endothelial growth factor (VEGF) is over-
expressed in psoriatic epidermis. Two tyrosine kinase
receptors for VEGF, Flt-1, and KDR, are also overexpressed
in psoriatic dermal microvessels (Detmar et al, 1994). These
reports suggest that VEGF might play an important role in
the pathogenesis of psoriasis. But the mechanisms respon-
sible for overexpression of VEGF in psoriasis are still
unclear.
Insulin-like growth factor II (IGF-II) is homologous to pro-
insulin in both sequence and structure (Cohick and
Clemmons, 1993). IGF-I and IGF-II can stimulate mitogen-
esis in a variety of cells (Daaghaday and Rotwein, 1989;
Stewart Claire and Rotwein, 1996), including normal and
transformed human keratinocytes (Neely et al, 1991).
Moreover, the level of IGF-II but not IGF-I was significantly
elevated in serum and blister fluid from psoriatic lesions (Xu
et al, 1996); however, the function of IGF-II in psoriasis has
not been well investigated. We have previously demon-
strated that IGF-II-induced VEGF expression in human
hepatoblastoma HepG2 cells (Kim et al, 1998). These
findings point to the possibility that IGF-II induces VEGF
expression and subsequently activates angiogenesis in
psoriasis as well.
It has been reported that IGF-II functions via IGF-I
receptors as a potent mitogen in many cell types including
keratinocytes (Neely et al, 1991; Hodak et al, 1996). IGF-I
activates extracellular signal-regulated kinase (ERK1) and
ERK2 (MAP kinase) in cultured rat cardiac myocytes
and HCT116 human colon carcinoma cells through IGFR-I
(Foncea et al, 1997; Fukuda et al, 2002). Therefore, these
findings suggested that IGF-II induction of VEGF expression
might be mediated through MAP kinase pathway.
HIF-1, a basic–helix–loop–helix–PAS transcription factor,
activates transcription of genes whose protein products
increase O2 availability or promote metabolic adaptation to
1These are co-first authors.
Abbreviations: ERK, extracellular signal-regulated kinase; HIF-1a,
hypoxia-inducible factor-1a; IGF-II, insulin-like growth factor II;
VEGF, vascular endothelial growth factor
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low oxygen tension. Examples include erythropoietin, VEGF,
glucose transporters, and glycolytic enzymes. Previous
studies demonstrated that exposure of human embryonic
kidney 293 cells to IGF-II-induced HIF-1a expression
(Feldser et al, 1999). The precise mechanism by which
IGF-II induced HIF-1a expression, however, has not been
investigated. HIF-1 consists of two subunits, HIF-1a and
HIF-1b (Wang et al, 1995). A decrease in cellular O2 tension
leads to elevation of HIF-1 activity via stabilization of the
HIF-1a protein; conversely, ubiquitin-mediated proteolysis
of HIF-1a on re-exposure to a normoxic environment results
in rapid decay of HIF-1 activity (Semenza and Wang, 1992;
Wang et al, 1995; Salceda and Caro, 1997; Huang et al,
1998; Kallio et al, 1999). Previous studies demonstrated that
genetic inactivation of p53 in cancer cells provides a potent
stimulus for tumor angiogenesis and that p53 inhibits HIF-1
activity by targeting the HIF-1a subunit for ubiquitination
and proteosomal degradation (Ravi et al, 2000). Conversely,
the loss of p53 enhances HIF-1-dependent expression of
VEGF in tumor cells (Ravi et al, 2000).
To investigate whether angiogenic properties of IGF-II
are mediated through the induction of VEGF synthesis by
the abnormal keratinocytes characteristic of psoriasis, we
examined effects of IGF-II on the induction of VEGF in the
immortalized HaCaT keratinocyte cells. Our results demon-
strated that IGF-II induces VEGF expression by upregulat-
ing HIF-1a through the MAP kinase (ERK1/2), MDM2, and
p53 pathways.
Results
IGF-II induces the expression of VEGF in HaCaT
keratinocytes Since IGF-II but not IGF-I was increased
abundantly in psoriatic lesions (Xu et al, 1996), we
supposed the role of IGF-II in psoriasis to be important.
To determine whether IGF-II might be involved in psoriatic
angiogenesis, we asked if IGF-II might induce the expres-
sion of VEGF in HaCaT keratinocytes. As shown in Fig 1,
VEGF mRNA level was approximately 4-fold higher in IGF-II-
treated HaCaT cells than that of untreated controls (Fig 1A).
To confirm our in vitro model, we examined VEGF
expression in HaCaT under conditions of reduced oxygen
(1% O2), a strong stimulus for VEGF (Detmar et al, 1997). As
expected, hypoxia strongly induced the expression of VEGF
mRNA (Fig 1A).
We then performed western blot analysis of VEGF in the
conditioned media and protein extracts from HaCaT cells
after treatment with IGF-II and found about 2.3-fold
increase in secreted VEGF levels (Fig 1B). As shown in Fig
1C, induction of VEGF protein level was concentration
dependent with the maximal effect at 200 ng per mL of IGF-
II. Moreover, we performed western blot analysis at several
time points (2, 4, 8, and 16 h). Induction of VEGF by IGF-II
was detected at 16 h but the level was lower than at 24 h
(data not shown). Therefore, we performed the following
experiments to delineate the mechanisms involved in
expression of VEGF at 24 h. Loading protein levels were
equivalent as measured by immunoblot using antibody
against a-tubulin. These data demonstrated that IGF-II
strongly upregulates VEGF mRNA and protein levels in
HaCaT cells.
IGF-II activates ERK1/2 phosphorylation in HaCaT
cells IGF-II functions via IGF-I or IGF-II receptors as a
potent mitogen for many cell types (Neely et al, 1991) and
IGFR-I has been reported to activate ERK1/2 in rat cardiac
myocytes and HCT116 human colon carcinoma cells
(Foncea et al, 1997, 2002). To investigate whether IGF-II
would activate ERK1/2 in keratinocytes, we examined
phosphorylation status of ERK1/2 in HaCaT cells. Activation
of ERK1/2 was determined by western blotting with
phospho-specific anti-ERK1/2, which detects only phos-
phorylated, activated ERK1/2. Selective increases in phos-
pho-ERK2 were seen within 5 min of stimulation, peaked at
30 min (Fig 2A) and returned to baseline levels after 2 h
(data not shown). In contrast, treatment with IGF-II had no
effect on members of the MAP kinase pathway involving
p38 (Fig 2B) or JNK1/2 (Fig 2C).
To confirm the importance of the ERK2 pathways in
response to stimulation with IGF-II, we treated cells with
PD98059 that specifically inhibits the upstream ERK acti-
vator, MAP kinase/ERK kinase (MEK) (Alessi et al, 1995). As
a control, we also treated the cells with SB203580, a
specific inhibitor of p38. As shown in Fig 3A, IGF-II-induced
phosphorylation of ERK2 was almost completely inhibited
by addition of PD98059 at 50 mM. The p38 inhibitor,
SB203580 (15 mM) had no effect on ERK2 phosphorylation.
Figure1
Insulin-like growth factor II (IGF-II) increases the expressions of
vascular endothelial growth factor (VEGF) mRNA and protein in
HaCaT keratinocytes. (A) Northern blot analysis of total RNA (20 mg
per lane) was performed. HaCaT cells were incubated with 100 ng per
mL IGF-II under 1% hypoxia for 24 h. The lower panels display an
image of the respective ethidium bromide (EtBr)-stained RNA gel to
demonstrate even loadings. Western blot analysis of the conditioned
media (B) and total cell lysates (C) were performed. HaCaT cells were
incubated with 100 ng per mL IGF-II (B) and increasing concentrations
of IGF-II (50–300 ng per mL) for 24 h (C). Con, control. The data are
representative of three independent experiments.
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The concentrations of MAP kinase inhibitors used in these
experiments did not affect cell viability. In control experi-
ments, the same amount of DMSO used as a vehicle did not
affect cell viability and activation of MAP kinases. The
involvement of ERK-signaling pathway on IGF-II-induced
VEGF expression was determined by western blot analysis.
As shown in Fig 3B, treatment with PD98059 attenuated
IGF-II-induced VEGF expression in HaCaT keratinocytes.
Therefore, these results suggest that VEGF induction by
IGF-II may be mediated by the activation of ERK.
Reduction of p53 but induction of MDM2 by IGF-II in
HaCaT cells Because psoriasis is a hyperproliferative skin
disease and p53 expression is reduced in psoriatic lesions
(Michel et al, 1996), we studied whether IGF-II was able to
reduce the expression of p53 in HaCaT cells. p53 was
analyzed by western blot analysis in IGF-II-treated HaCaT
cells. In IGF-II-treated cells, p53 levels were reduced at both
16 and 24 h after treatment with IGF-II (100 ng per mL)
(Fig 4).
To investigate the mechanism responsible for IGF-II-
induced changes in p53 expression, we first examined the
expression of MDM2 that targets p53 in the cytoplasm for
destruction in proteosome-dependent pathways. As shown
in Fig 5A, MDM2 levels increased concentration depen-
dently with treatment of IGF-II. In addition, MDM2 was
significantly induced at 16 and 24 h in a time-dependent
manner (Fig 5B). The exposure of HaCaT cells to IGF-II in
the presence of PD98059 attenuated MDM2 expression to
the basal level (Fig 5C). In contrast, the expression of p53
was recovered by co-treatment of PD98059 to the basal
Figure3
Inhibition of ERK1/2 by PD98059 after IGF-II treatment. HaCaT cells
were pretreated for 30 min with PD98059 (50 mM) or SB203580 (15 mM)
before treatment of IGF-II (100 ng per mL) and then incubated for 24 h.
Cell lysates (40 mg per lane) were isolated and immunoblot analysis was
performed with anti-phospho ERK1/2, total ERK1/2 antibodies (A) or
anti-VEGF antibody (B). Relative protein amounts in each sample were
checked by expression of a-tubulin. These data are repeated by three
times individually.
Figure 2
Time-dependent activation of extracellular signal-regulated kinase
(ERK1/2) by insulin-like growth factor II (IGF-II). Confluent HaCaT
cells were treated with IGF-II (100 ng per mL) and monitored for 5–30
min. Total cell lysates were extracted at the indicated times, and then
immunoblotted with anti-phospho ERK1/2, anti-phospho p38, anti-
phospho JNK1/2, ERK1/2, p38, or JNK1/2 antibodies as described
Materials and Methods. Con, control. The data are representative of
three independent experiments.
Figure4
Reduced level of p53 by IGF-II in HaCaT cells. HaCaT cells were
treated with IGF-II (100 ng per mL) for 16 or 24 h. Immunoblot analysis
of total cell lysates (40 mg per mL) was performed using anti-p53
antibody. Relative protein amounts in each sample were checked by
expression of a-tubulin. Con, control. The data are representative of
three independent experiments.
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level (Fig 5D), suggesting that IGF-II might downregulate
p53 by MDM2 through the ERK signaling pathway.
Induction of HIF-1a by IGF-II in HaCaT cells Recently,
it has been reported that p53 reduced the stability and
expression level of HIF-1a in cancer cells (Ravi et al, 2000)
and IGF-II-induced expression of HIF-1a in human embryo-
nic kidney 293 cells (Feldser et al, 1999). In this study, IGF-II
was found to reduce the level of p53 mediated by Mdm2
in HaCaT cells, which might increase HIF-1a expression
by abrogating p53-mediated HIF-1a degradation. Thus, to
determine whether IGF-II induces HIF-1a in keratinocytes,
western blot analysis for HIF-1a was performed in HaCaT
cells. As shown in Fig 6A, IGF-II induced the protein
expression of HIF-1a in HaCaT cells. Because hypoxia is a
potent inducer of HIF-1a, hypoxia was used as a positive
control for HIF-1a (Fig 6A). The exposure of HaCaT cells to
IGF-II in the presence of PD98059 downregulated HIF-1a
to the basal level (Fig 6B). Therefore, IGF-II induces the
expression of HIF-1a, which in turn might upregulate the
expression of VEGF.
Discussion
In several conditions including wound healing, bullous
diseases with subepidermal blister formation, epidermal
keratinocytes overexpress VEGF mRNA, and dermal micro-
vascular endothelial cells overexpress mRNA encoding
both VEGF receptors, Flt-1 and KDR (Brown et al, 1992).
VEGF and its receptors are also overexpressed in many
tumors such as squamous cell carcinomas of the skin
(Weninger et al, 1996) and in chronic inflammatory states
including psoriasis (Detmar et al, 1994). All of these
conditions are characterized by microvascular hyperperme-
ability and angiogenesis (Dvorak et al, 1986). It has been
reported that VEGF is highly induced in many tumors by a
Figure6
IGF-II induces the protein level of HIF-1a through MAP kinase in
HaCaT cells. (A) Immunoblot analysis of total lysates (40 mg) was
performed using anti-HIF-1a antibody. HaCaTcells were incubated with
100 ng per mL IGF-II for 16 or 24 h or under hypoxia (1% O2) in the
presence of 10% serum for 4 h. (B) HaCaT cells were pretreated for 30
min with PD98059 (50 mM) before treatment of IGF-II (100 ng per mL)
and incubated for 24 h. Following total proteins (40 mg per lane) were
isolated and immunoblot analysis was performed with anti-HIF-1a
antibody. Relative protein amounts in each sample were checked by
expression of a-tubulin. The data are representative of three experi-
ments.
Figure 5
Induced level of MDM2 by IGF-II in a concentration- and a time-
dependent manner in HaCaT cells. (A) HaCaT cells were treated with
IGF-II (50 or 100 ng per mL) for 24 h. Immunoblot analysis of total cell
lysates (40 mg per mL) was performed using anti-MDM2 antibody. (B)
HaCaT cells were treated with 100 ng per ml IGF-II for 16 or 24 h.
Following total proteins (40 mg per lane) were isolated and immuno-
blotting was performed with anti-MDM2 antibody. (C, D) HaCaT cells
were pretreated for 30 min with PD98059 (50 mM) before treatment of
IGF-II (100 ng per mL) and incubated for 24 h. Following total proteins
(40 mg per lane) were isolated and immunoblotting was performed with
anti-MDM2 antibody (C) or anti-p53 antibody (D). Relative protein
amounts in each sample were checked by expression of a-tubulin. Con,
control. The data are representative of two experiments.
IGF-II/VEGF EXPRESSION IN HaCaT 155123 : 1 JULY 2004
number of diverse stimuli, including nitric oxide, glucose,
hormones, cytokines, angiogenic factors themselves, and
hypoxia (Brown et al, 1997), but in psoriasis, regulators
involved in VEGF induction until now remain unknown.
Recently it has been reported that HaCaT cells synthe-
size IGF-II, IGFBP-3, IGFBP-6, IGFBP protease but not IGF-
I. The presence of these components of the IGF system
indicates that an autocrine of IGF-II loop may be a potent
contribution to psoriatic keratinocyte proliferation. The IGF-I
level in tissue fluid from the involved psoriatic area was
similar to that from the uninvolved areas but the IGF-II level
was significantly elevated in the involved areas (Xu et al,
1996). These findings indicated that IGF-II has more
important roles than IGF-I in psoriasis. IGF-II is a well-
known mitogen for keratinocytes and also has a potent
angiogenic activity (Daaghaday and Rotwein, 1989; Lee
et al, 2000). It is still questionable, however, whether IGF-II
is responsible for angiogenesis seen in psoriasis. Pre-
viously, we demonstrated that IGF-II could induce VEGF
expression in human hepatoblastoma cell line HepG2 cells
(Kim et al, 1998). Therefore, we proposed that IGF-II might
induce the expression of VEGF and play important roles in
inducing angiogenesis in psoriasis.
In this study, we demonstrated that IGF-II functioned as a
potent inducer of VEGF synthesis by the immortalized
keratinocyte cell line HaCaT (Fig 1). Although the correlation
between HaCaT cells and psoriasis is unclear, it is still
possible that IGF-II has a similar effect on the induction of
VEGF in the psoriatic diseases. Moreover, in many cases,
VEGF induced by various factors has a potent angiogenic
effect; therefore, IGF-II and IGF-II-induced VEGF may both
contribute to psoriatic angiogenesis.
The significance of IGF-II-induced VEGF was underlined
by the fact that VEGF was not induced by other cytokines
associated with psoriasis, such as interleukin-1, interleukin-
6, interleukin-8, tumor necrosis factor-a, and TGF-b in
human keratinocytes (Detmar et al, 1995; Trompezinski et al,
2002). Recently, it was reported that hepatocyte growth
factor/scatter factor (HGF/SF)-induced VEGF expression in
human keratinocytes (Gille et al, 1998; Wojta et al, 1999;
Reisinger et al, 2003), but the mechanism of HGF-induced
VEGF expression has not been well defined.
It was reported that antisense oligonucleotides of IGFR-I
caused a normalization of the hyperplastic epidermis in
psoriasis (Christopher et al, 2000) and IGF-II functioned via
IGF-I receptors as a potent mitogen in keratinocytes (Neely
et al, 1991). Thus, the elevated IGF-II level in psoriasis may
play an important role in epidermal hyperproliferation
through IGFR-I. This suggestion correlates well with the
findings that IGFR-I is overexpressed in psoriatic lesion and
involved in hyperproliferation of psoriatic epidermis (Krane
et al, 1992). In addition, IGFR-I is known to transduce
extracelluar signals through MAP kinase pathways (Foncea
et al, 1997, 2002). Therefore, we examined the MAP kinase
pathway to investigate signal transduction mechanisms
involved in IGF-II-induced VEGF expression. As shown in
Fig 2, we demonstrated that ERK2 was phosphorylated by
IGF-II in HaCaT keratinocytes. We also found that VEGF
expression induced by IGF-II was remarkably inhibited in
the presence of a specific inhibitor of the upstream ERK
activator MAP kinase/ERK kinase (MEK), PD98059 (Fig 3).
Three structurally related but biochemically and func-
tionally distinct MAP kinase signal transduction pathways
include the ERK, c-jun N-terminal kinases (JNK) or stress-
activated protein kinase and p38 MAP kinase (Su and Karin,
1996). Individual MAP kinase subtypes appear to have
equivalent but distinct upstream kinases that are activated
by a wide variety of extracellular stimuli. Some extracellular
stimuli appear to activate multiple MAP kinase pathways,
whereas other signals activate only a single pathway
(Assefa et al, 1997). In this study, we found that IGF-II
treatment of HaCaT keratinocytes may activate a single
MAP kinase pathway, ERK but not p38 or JNK (Fig 2).
Because ERK1/2 activation is associated with expression
of several genes including MMP-1 (Watts et al, 1998),
interleukin-6 (Hayashi et al, 2000), cyclooxygenase-2 (Niiro
et al, 1998), and MDM2 (Ries et al, 2000), IGF-II may
activate many other genes in psoriasis and other patholo-
gical conditions associated with elevated expression of
IGF-II. Elucidation of other genes induced by IGF-II through
ERK1/2 may help to explain the pathogenesis of psoriasis.
The normal p53 tumor suppressor protein mediates both
growth arrest and apoptosis whereas mutant forms are
associated with tumorigenesis. Interestingly, it was reported
that p53 expression was reduced in psoriatic lesions
(Michel et al, 1996); however, the mechanisms responsible
for and consequences of reduced p53 expression in
psoriasis had not been investigated. In this report, we
found that IGF-II-induced MDM2, a potent inhibitor of p53,
might degrade p53 through a proteasome-dependent
pathway (Haupt et al, 1997; Kubbutat et al, 1997) (Figs 4
and 5). It has been reported that activation of the Ras/Raf/
MEK/MAP kinase signaling cascade results in elevated
levels of MDM2 (Persons et al, 2000). We demonstrated that
IGF-II induced the activation of MEK and ERK2 in HaCaT
cells (Figs 3 and 4) and IGF-II-induced MDM2 was
dramatically reduced by PD98059 treatment (Fig 5C).
Therefore, IGF-II stimulates the expression of MDM2 protein
through the Ras/Raf/MEK/MAP kinase cascade.
Recently, it has been reported that p53 repressed HIF-1-
stimulated transcription (Blagosklonny et al, 1998) through
degradation of HIF-1a. Loss of p53 in tumor cells enhances
HIF-1a levels and increases the transcriptional activity of
VEGF gene under hypoxia (Ravi et al, 2000). These results
support that amplification of normal HIF-1-dependent
responses to hypoxia via loss of p53 function contributes
to the angiogenic switch during tumorigenesis.
Therefore, a loss of p53 function by IGF-II-induced
MDM2 or p53 mutation given to HaCaT cells might
contribute for the induction of HIF-1a. In this report, we
showed that the reduced level of p53 and the over-
expression of HIF-1a result secondarily in stimulation of
VEGF expression in HaCaT cells (Figs 5 and 6).
Moreover, it has been demonstrated that IGF-I can
induce the HIF-1 protein expression through the MAP
kinase pathway (Fukuda et al, 2002). They reported that
IGF-I-activated MAP kinase via IGF-1R and ERK activation
of the transcriptional factor eIF-4E, and finally, eIF-4E
induces synthesis of HIF-1a. Many of these data are
consistent with our results. Therefore, we suggest that
IGF-II might be involved in the synthesis of HIF-1a induced
by the MAP kinase pathway.
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Although HaCaT cells are widely used as a model for
primary normal keratinocytes, retinoids, or UV irradiation
showed different effects on VEGF expression in primary
keratinocytes and HaCaT cells (Weninger et al, 1998;
Mildner et al, 1999). Thus we have tried to elucidate
IGF-II-mediated HIF-1a/VEGF signaling pathways in pri-
mary normal keratinocytes as well. We found, however,
that normal primary keratinocytes exerted no significant
changes of VEGF, p53, and HIF-1a expressions in response
to IGF-II (data not shown), in contrast with HaCaT cells.
From these results, we assumed that these different effects
between two type cells might come from different culture
conditions or unidentified reasons. Therefore, the elucida-
tion of pathogenesis of psoriasis should be dealt with
careful examinations, because the correlation between
HaCaT cells and primary/psoriatic keratinocytes remains
still unclear.
In conclusion, we suggest that IGF-II induces angiogen-
esis and microvascular permeability by the increased
expression of VEGF in HaCaT keratinocytes. The mechan-
ism of VEGF expression might be through a pathway in
which IGF-II activates HIF-1a via ERK pathway. The
activated ERK induces MDM2, MDM2 in turn degrades
p53, and finally the loss of p53 induces HIF-1a in HaCaT
cells. These results may provide an important clue to
understand possible pathogenetic mechanisms associated
with VEGF expression and the function of IGF-II in psoriasis.
Materials and Methods
Recombinant IGF-II was purchased from R&D (Minneapolis,
Minnesota). Anti-VEGF antibodies were obtained from Santa Cruz
(Santa Cruz, California) and anti-HIF-1a antibody was from BD
Transduction Laboratories (BD Biosciences Pharmingen, Chicago,
Illinois). Anti-ERK, phospho-ERK, p38, phospho-p38, JNK, phos-
pho-JNK antibodies were kindly provided by Dr Rony Seger
(Weizmann Institute of Science, Rehovot, Israel). A specific in-
hibitor of MEK1, PD98059 and specific inhibitor of p38, SB203580
were obtained from Calbiochem, Inc., La Jolla, California, and
stock solutions prepared in dimethyl sulfoxide (DMSO).
Cell culture The differentiated human keratinocyte cell line HaCaT
was kindly provided by Dr N. Fusenig, German Cancer Research
Center (Heidelberg, Germany). The cells were maintained as
monolayer cultures in Dulbecco’s modified eagle medium (DMEM;
Life Technologies, Gaithersburg, Maryland), supplemented with
10% fetal bovine serum (FBS; Life Technologies), 100 U per mL of
penicillin and 100 mg per mL of streptomycin (Life Technologies) at
371C in a humidified incubator under 5% CO2. Cells were seeded
at a density of 1  106 cells/100 mm dishes. After 48 h, cells were
washed with serum-free media, replaced with 10 ml of media
without FBS and incubated in a humidified incubator (Forma
Scientific Inc., Marietta, Ohio) with an interior temperature of 371C
for at least 18 h prior to experiments examining IGF-II treatment.
Northern blot analysis Total RNA were isolated from cells treated
with IGF-II (100 ng per mL) (R&D) and hypoxia using TRI reagent
(Life Technologies). RNA (20 mg) was electrophoresed on 1.2%
agarose/6.6% formaldehyde gels, transferred to Zeta-Probe nylon
membrane (Bio-Rad Lab., Richmond, California), and was cova-
lently linked by UV cross-linker (UV Stratalinker 1800; Stratagene,
La Jolla, California). Hybridization was then performed with the
addition of 20 ng of a-32P-labeled VEGF cDNA probes at 421C for
16 h. Membrane was washed twice with washing solution
(0.5  SSC/0.1% SDS) at 501C for 30 min, and exposed to X-ray
film with intensifying screens at 701C for 24 h. a-32P-labeled DNA
probes were prepared by using random primer oligonucleotides
(Rediprime DNA Labeling System; Amersham Pharmacia Biotech,
Buckinghamshire, UK).
Immunoblot analysis Cells were treated with IGF-II for 24 h and
lysed with buffer containing 40 mM Tris-HCl, pH 7.4, 10 mM EDTA,
120 mM NaCl, 1 mM dithiothreitol, 0.1% noniodet P-40, and
protease inhibitors. Total proteins were electrophoresed using 15%
reducing polyacrylamide gels. Immunoblot analysis was performed
using anti-VEGF (Santa Cruz), DO1 (anti-p53 antibody, Santa Cruz),
MDM2 (Santa Cruz), and HIF-1a (BD Biosciences Pharmingen)
polyclonal antibody with emission chemiluminescence-based
detection.
Detection of ERK1/2 for analysis of MAPK HaCaT cells were
treated with IGF-II (100 ng per mL) for indicated times and
immediately lysed in lysis buffer (25 mM Hepes, pH 7.6, 0.3 M
NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.1% Triton X-100, 0.5 mM
DTT, 0.1 mM sodium orthovanadate, 20 mM b-glycerophosphate,
4 mM p-nitrophenyl phosphate, 20 mg per mL leupeptin, 1 mM
PMSF). Total proteins were used for immunoblot analysis with anti-
phospho-ERK, phospho-p38, phospho-JNK antibodies, and anti-
ERK, anti-p38, anti-JNK antibodies.
Detection of VEGF expression by IGF-II in the conditioned
media HaCaT cells were treated with IGF-II (100 ng per mL) for 24
h in serum-free media and immediately the conditioned media was
prepared with trichloroacetic acid (TCA) protein precipitation. BCA
protein assay was performed to measure the protein concentra-
tion. Total proteins were used for immunoblot analysis with anti-
VEGF (Santa Cruz) antibody.
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